Jump to content

Draft:James Lamar Wittliff

From Wikipedia, the free encyclopedia
  • Comment: Heavily refbombed article about an American biochemist. Ref. 23 is the only reliable secondary source I can see in the list, the rest are mostly articles by the subject or trivial mentions. Is this enough for an article? WeirdNAnnoyed (talk) 14:04, 15 December 2024 (UTC)
James Lamar Wittliff
Born(1938-06-15)June 15, 1938
Taft, Texas
EducationUniversity of Texas at Austin (B.A., Ph. D.)
Louisiana State University School of Medicine (M. S.)
Known forQA surveys for Cooperative Clinical Trial Groups for estrogen & progestin receptors and Co-Developer with NEN/DuPont of First FDA approved kits [1] [2] of these biomarkers
Scientific career
FieldsBiochemistry & Laboratory Medicine
InstitutionsUniversity of Rochester
University of Louisville
Doctoral advisorRobert L. Airth
Notable studentsDavid G. Gardner
de:Herbert Zech

James Lamar Wittliff (born June 15th, 1938) also known as Jim Wittliff, is an American Biochemist and Professor Emeritus of Biochemistry & Molecular Genetics at the University of Louisville. He was Chairman of the Department of Biochemistry at the University of Louisville School of Medicine and Dentistry from 1976-1983.[3]. Wittliff's laboratory was designated the National Reference Facility by the National Cancer Institute for performing quality assurance surveys of receptor testing for cooperative clinical trial groups in the United States and Canada.[1] [4][5][6] He is the co-developer with NEN/DuPont [7] of the 1st FDA approved tests for quantifying levels of estrogen and progestin receptor proteins. [2][8]

Early life and education

[edit]

Wittliff was born on June 15, 1938 in Taft, Texas, of primarily Eastern European heritage. He is a direct descendant of John Cryer (Crier)[9], who were recruited to settle Texas as part of Stephen F. Austin’s original 300 families. He, his brother Bill and their mother Laura moved to Blanco when they were boys. In 1956, Wittliff graduated from San Marcos Academy, a college preparatory school that emphasized military discipline and training at the time. After 2 years of studying Chemical Engineering at Texas Tech University, he received a bachelor’s degree in chemistry from University of Texas at Austin. While at UT, Wittliff worked at Clyde Campbell University Shop and modeled to support his education.[10] Wittliff then earned an M. S. Degree in Biochemistry at Louisiana State University, School of Medicine. Wittliff’s family moved to the University of Texas at Austin where he was awarded an National Defense Education Act (NDEA) Fellowship, a program influenced by the launch of the Sputnik satellite by the Soviets. Wittliff received his Ph.D. degree at The University of Texas at Austin in 1967. He then received an NIH Postdoctoral Award to study in the Laboratory of Professor Francis T. Kenney in the Biology Division at Oak Ridge National Laboratory.

Career

[edit]

In 1969, Wittliff was recruited to the Department of Biochemistry at the University of Rochester School of Medicine as an assistant professor to work with Thomas C. Hall[11], a co-founder of the sub-specialty of medical oncology, to develop the new Cancer Center. In 1975, Wittliff was promoted to Associate Professor of Biochemistry and Head on the Section on Endocrine Biochemistry in the Cancer Center. In 1976, the University of Louisville School of Medicine and Dentistry recruited Wittliff as Chairman of the Department of Biochemistry, a position he would hold until 1983. He was also actively involved in the development of the first Cancer Center there. Although Wittliff began developing assays that quantified estrogen and progestin receptor proteins using radio-labeled steroid ligands while at Rochester, it was in Louisville that he collaborated with New England Nuclear (NEN, later NEN/DuPont) to develop the first FDA-Approved Assay Kits for quantifying these clinically relevant biomarkers[1] [2]

Upon arrival at the University of Louisville, Wittliff also established a clinical laboratory certified by the Commonwealth of Kentucky and CLIA to provide clinically relevant assays that quantified levels of estrogen and progestin receptor proteins for breast cancer management. This led Wittliff and his group to develop reference materials for these protein biomarkers and establishment of Quality Assurance Programs for standardizing determinations of estrogen and progestin receptor proteins in breast cancer biopsies. Hundreds of laboratories engaged in cooperative clinical trials of breast cancer treatment by groups such as the NSABP[12], CALGB[13],ECOG[6][14], NCCTG[15], SECSG[16][17] and SWOG[18] participated in NCI-sponsored QA Surveys established by Wittliff. These QA programs were extended to the College of American Pathologists[19] [20] and international investigators[21] to standardize determinations of these biomarkers for routine assessment by all clinical laboratories. [20]

Personal Life

[edit]

He is the older of two children of Laura (née Sachtleben) Wittliff and William Albert Wittliff. Wittliff's brother William D. Wittliff was an American screenwriter and photographer. Various of Wittliff’s and his brother's childhood experiences during World War II were depicted in the film Raggedy Man (1981). While in college, Wittliff was a member of the Kappa Sigma fraternity and later received the John G. Tower Distinguished Alumni Award[22]. He married Theresa H. "Mitzie" Wittliff (née Hano) and had two sons. Later she also became his collaborator. Wittliff is widely known as an Oenophile having served as President of the Kentucky Chapters of the American Wine Society and of the American Institute of Wine & Food. He was also a founding member of the Kentucky Chapter of Confrérie de la Chaîne des Rôtisseurs.

Awards and Accolades

[edit]

1984 Elected Fellow of the National Academy of Clinical Biochemistry (now FADLM) [23]

1988 Distinguished Scientist Award, (Clinical Ligand Assay Society)[24]

1990-92 Co-Editor-in-Chief, Clinical Biochemistry

1996-97 President, International Clinical Ligand Assay Society [24]

1998 Doctor of Medicine honoris causa (Leopold-Franzens-Universität Innsbruck, Austria)[25][26]

1998 University of Louisville Symposium honoring the career of James L. Wittliff, Ph. D., M. D. hc[27]

2001 American Association for Clinical Chemistry (Award for Outstanding Contributions to Clinical Chemistry in a Selected Area of Research)[23]

2001 American Association for Clinical Chemistry (Hall of Fame recognition)[23]

2004 Goldsmith Research Excellence Award, American Cancer Society, Kentucky Division

2008 President’s Award for Career Achievements: Outstanding Scholarship, Research and Creative Activity, University of Louisville

2012 The CPT Paul W. Peña Outstanding Alumni Award - San Marcos Academy, San Marcos, TX[28]

2014 Morton K. Schwartz Award (for Significant Contributions in Cancer Research Diagnostics American Association for Clinical Chemistry) [29] [23]

2015 - Present: Wittliff Lecture Series at San Marcos Academy honoring his career contributions [28]

2021 John G. Tower Distinguished Alumni Award, Texas Tech University, Kappa Sigma Fraternity [22]

References

[edit]
  1. ^ a b c DeSombre, E. R., Carbone, P. P., Jensen, E. V., McGuire, W. L., Wells, S. A., Jr., Wittliff, J. L. and Lipsett, M. B. Steroid Receptors in Breast Cancer. New England J. Med., 301:1011-1012, 1979.[1] Retrieved October 4, 2024.
  2. ^ a b c New England Nuclear (NEN) Estrogen Receptor Assay Kits Approvable by FDA: Medical Devices, Diagnostics & Instrumentation Reports, p.3, January 19, 1981 (ISSN 0163-2426. https://portal.issn.org/resource/ISSN/0163-2426#) Retrieved October 4, 2024.
  3. ^ History of the Department of Biochemistry and Molecular Genetics at the University of Louisville School of Medicine.[2] Retrieved October 4, 2024.
  4. ^ Wittliff, J. L., Fisher, B., and Durant, J. R. Establishment of Uniformity in Steroid Receptor Analyses Used In Cooperative Clinical Trials of Breast Cancer Treatment. In: B. Henningsen, F. Linder and C. Steichele (eds.), Recent Results in Cancer Research, Vol. 71, pp. 198-206, Heidelberg: Springer-Verlag, 1980. Retrieved October 7, 2024.
  5. ^ Wittliff, J. L., Brown, A. M. and Fisher, B. Establishment of Uniformity in Steroid Receptor Determinations for Protocol B-09 of the National Surgical Adjuvant Breast Project. In: G. A. Sarfaty, A. R. Nash and D. D. Keightley (eds.), Estrogen Receptor Assays in Breast Cancer: Laboratory Discrepencies and Quality Assurance, pp. 27-42, New York: Masson Publishing USA, Inc., 1981.
  6. ^ a b Cohen, J. L., Raam, S., Gelman, R., and Wittliff, J. L. A Blinded Study of Inter- and Intra-Laboratory Variations in the Performance of Estrogen Receptor (ER) Assay. In: G. A. Sarfaty, A. R. Nash and D. D. Keightley (eds.), Estrogen Receptor Assays in Breast Cancer: Laboratory Discrepencies and Quality Assurance, pp. 43-56, New York: Masson Publishing USA, Inc., 1981.
  7. ^ New England Nuclear Archive in Science History Institute Muesum and Library [3] Retrieved October 4, 2024.
  8. ^ Fisher, B., Redmond, C., Brown, A., Womark, N., Wittliff, J. L. et al. Treatment of Primary Breast Cancer with Chemotherapy and Tamoxifen. New England J. Med., 305:1-6, 1981.[4] Retrieved October 4, 2024.
  9. ^ "Crier, John".
  10. ^ Clyde Campbell University Shop Tie & Obituary of Clyde Campbell[5] [6]
  11. ^ "Thomas C. Hall".
  12. ^ Wittliff, J. L., Brown, A. M. and Fisher, B. Establishment of Uniformity in Steroid Receptor Determinations for Protocol B-09 of the National Surgical Adjuvant Breast Project. In: G. A. Sarfaty, A. R. Nash and D. D. Keightley (eds.), Estrogen Receptor Assays in Breast Cancer: Laboratory Discrepancies and Quality Assurance, pp. 27-42, New York: Masson Publishing USA, Inc., 1981.
  13. ^ Wittliff, J. L. and Wiehle, R. D. Analytical Methods for Steroid Hormone Receptors and their Quality Assurance. In: Hollander, V. P. (ed.), Hormonally Responsive Tumors, Chapter 15, pp. 383-428, New York: Academic Press, Inc., 1985.
  14. ^ Raam, S., Gelman, R., Cohen, J. L. and Wittliff, J. L. et al. Estrogen Receptor Assay: Interlaboratory and Intralaboratory Variations in the Measurement of Receptors Using Dextran-coated Charcoal Technique: A Study Sponsored by E.C.O.G. Eur. J. Cancer, 17:643-649, 1981.
  15. ^ Wittliff, J. L. Steroid Receptor Analyses, Quality Control, and Clinical Significance. In: W. L. Donegan and J. S. Spratt (eds.), Cancer of the Breast, Chapter 11, pp. 303-335, Philadelphia, PA: W. B. Saunders Co., 1988.
  16. ^ Wittliff, J. L., Wiehle, S. A., Eckman, J. B., Jr., Smalley, R. V., Bartolucci, A. A. and Durant, J. R. A Quality Assurance Program for Steroid Receptor Analyses Used by the Southeastern Cancer Study Group (SECSG). In: G. A. Sarfaty, A. R. Nash and D. D. Keightley (eds.), Estrogen Receptor Assays in Breast Cancer: Laboratory Discrepencies and Quality Assurance, pp. 105-125, New York: Masson Publishing USA, Inc., 1981.
  17. ^ Smalley, R. V., Bartolucci, A. A., Moore, M., Vogel, C., Carpenter, J., Perez, C. A., Velez-Garcia, E., Marcial, V., LeFante, J., Wittliff, J. L., Ketcham, A. and Durant, J. Southeastern Cancer Study Group: Breast Cancer Studies 1972-1982. Int. J. Radiation Oncol. Biol. Phys., 9:1867-1874, 1983.
  18. ^ Wittliff, J. L., Pasic, R. and Bland, K. I. Steroid and Peptide Hormone Receptors: Methods, Quality Control and Clinical Use. In: K. I. Bland and E. M. Copeland III (eds.), The Breast: Comprehensive Management of Benign and Malignant Diseases, Chapter 25, pp. 458-498, Philadelphia, PA: W. B. Saunders Co., 1998.
  19. ^ Oxley, D. K., Haven, G. T., Wittliff, J. L. and Gilbo, D. Precision in Estrogen and Progesterone Receptor Assays: Results of the First CAP Pilot Survey. Amer. J. Clin. Pathol., 78:587-596, 1982.
  20. ^ a b Hammond, M.E.H., et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. (Unabridged Manuscript at www.ASCO.org) Arch. Pathol. Lab. Med. 134 (6): 907-22, 2010. PMID: 20524868
  21. ^ Jordan, V. C., Zava, D. T., Eppenburger, U., Kiser, A., Sebek, S., Dowdle, E., Krozowski, Z., Bennett, R. C., Funder, J., Holdaway, I. M. and Wittliff, J. L. Reliability of Steroid Hormone Receptor Assays: an International Study. Eur. J. Cancer Clin. Oncol., 19:357-363, 1983.
  22. ^ a b "John G. Tower Award".
  23. ^ a b c d The Association for Diagnostics & Laboratory Medicine (ADLM) James Wittliff Biography.[7] Retrieved October 4, 2024.
  24. ^ a b Chase, Grafton. CLAS at 20: A History. Journal of Clinical Immunoassay, 17 (1):17-23, 1994. Retrieved October 7, 2024.
  25. ^ Compiled by David E. Bruns Editor , The Clinical Chemist, Clinical Chemistry, Volume 47, Issue 7, 1 July 2001, Pages 1335–1342, https://doi.org/10.1093/clinchem/47.7.1335.[8] Retrieved October 4, 2024.
  26. ^
  27. ^
  28. ^ a b San Marcos Academy[9] Retrieved October 7, 2024.
  29. ^ ADLM Merit Awards: The Morton K. Schwartz Award for Significant Contributions in Cancer Research Diagnostics (Discontinued).[10] Retrieved October 4, 2024.
[edit]



This page will be placed in the following categories if it is moved to the article namespace.
Categories:
Retrieved from "https://en.wikipedia.org/w/index.php?title=Draft:James_Lamar_Wittliff&oldid=1263235126"